IMR Press / FBL / Volume 16 / Issue 1 / DOI: 10.2741/3672

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes
Show Less
1 UND Life Sciences, 13800 Fairhill Road, 321 Shaker Heights, OH 44120, USA. undurti@hotmail.com
2 Instituto de Biologia Celular, Facultad de Ciencias Medicas, Universidad Nacional de Cordoba, Ciudad Universitaria, Barros esquina Gordillo, Cordoba (5000), Argentina
3 CONICET, Argentina
Academic Editor:Undurti N. Das
Front. Biosci. (Landmark Ed) 2011, 16(1), 13–20; https://doi.org/10.2741/3672
Published: 1 January 2011
(This article belongs to the Special Issue Advances in metabolic syndrome and diabetes mellitus)
Abstract

Both hypertension and type 2 diabetes mellitus are common and there are no reliable markers either to predict their development or complications. High fat diet and carbohydrate-rich diet enhance serum asymmetrical dimethylarginine (ADMA) levels, an endogenous inhibitor of nitric oxide synthesis. ADMA levels are elevated in patients with hypertension, poor control of hyperglycemia, diabetic microangiopathy and macroangiopathy and dyslipidemia. One of the earliest signs of vascular dysfunction and insulin resistance, which are present in hypertension and type 2 diabetes mellitus, is an elevation in serum ADMA levels. Displacing plasma ADMA by oral supplementation of L-arginine restores endothelial dysfunction by augmenting endothelial nitric oxide generation. Strict control of hyperglycemia decreases serum ADMA levels. These and other studies suggest that serum ADMA levels could be used to predict the development of hypertension and type 2 diabetes mellitus in those who are at high-risk to develop these diseases.

Share
Back to top